v3.25.4
Capital Stock (Tables)
12 Months Ended
Sep. 30, 2025
Capital Stock [Abstract]  
Schedule of Black-Scholes Option Valuation Model, with the Following Weighted Average Assumptions

The fair values of these stock options were estimated at the dates of grant, which is August 6, 2025 for stock options granted in fiscal 2025 and October 19, 2023 for stock options granted in fiscal 2024, using the Black-Scholes Option Valuation Model, with the following weighted average assumptions:

 

   September 30,
2025
   September 30,
2024
 
Stock price  $0.54   $1.16 
Exercise price  $0.54   $1.16 
Expected risk free interest rate   3.77%   4.75%
Expected volatility   136.90%   166.40%
Expected life in years   5    5 
Expected dividend yield   nil    nil 
Grant date fair value per option  $0.48   $1.10 
Schedule of Outstanding Stock Options

A continuity schedule of outstanding stock options at September 30, and the changes during the periods, is as follows:

 

   Number of
Stock
Options
   Weighted
Average
Exercise
Price
 
       US$ 
Balance, September 30, 2023   455,000    3.73 
Granted   1,030,000    1.16 
Exercised   
    -
    
    -
 
Forfeited   
     -
    
     -
 
Balance, September 30, 2024   1,485,000    1.95 
Granted   1,030,000    0.54 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Balance, September 30, 2025   2,515,000    1.37 
Schedule of Outstanding Unvested Stock Options

A continuity schedule of outstanding unvested stock options at September 30, and the changes during the periods, is as follows:

 

   Number of
Unvested
Stock
Options
   Weighted
Average
Grant Date
Fair Value
 
       US$ 
Balance, September 30, 2023   22,500    2.11 
Granted   1,030,000    1.10 
Vested   (775,000)   1.19 
Forfeited   
      -
    
      -
 
Balance, September 30, 2024   277,500    1.10 
Granted   1,030,000    0.48 
Vested   (1,161,250)   0.68 
Forfeited   
      -
    
      -
 
Balance, September 30, 2025   146,250    0.61 
Schedule of Stock Options Outstanding and Exercisable

A summary of stock options outstanding and exercisable at September 30, 2025:

 

   Exercisable   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Life (Years)
 
       US$     
Grant date            
November 1, 2021   365,000    4.10    6.08 
December 30, 2022   90,000    2.21    7.25 
October 19, 2023   1,013,750    1.16    8.08 
August 6, 2025   900,000    0.54    9.83 

A summary of warrants outstandingand exercisable at September 30, 2025:

 

   Exercisable   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Life (Years)
 
       US$     
Grant date            
March 29, 2021   1,562,686    7.50    0.49 
January 8, 2024   400,000    2.00    3.27 
May 27, 2025   13,500,000    0.48    0.65 
August 26, 2025   253,425    0.73    4.90 
Schedule of Stock-Based Compensation Expense

A summary of stock-based compensation expense for the years ended September 30 2025, 2024 and 2023 is as follows:

 

   September 30,   September 30,   September 30, 
   2025   2024   2023 
   US$   US$   US$ 
             
Common share awards   524,280    834,399    1,796,179 
Stock option awards   448,599    1,142,787    265,631 
Total   972,879    1,977,186    2,061,810 
Schedule of Warrants

The continuity of the Company’s warrants is as follows:

 

   Number of
Warrants
   Weighted
Average
Exercise
Price
 
        US$ 
Balance, September 30, 2023   1,562,686    7.50 
Granted   400,000    2.00 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Balance, September 30, 2024   1,962,686    6.38 
Granted   13,753,425    0.48 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Balance, September 30, 2025   15,716,111    1.22